Vivian Schiedler, MD
Ophthalmic Plastic and Reconstructive Surgery · Ashland, ORNPI 1063423705
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (36.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Amgen at 49.6% of the total. Reporting peaked in 2023 at $2,089 and has fallen 93.3% since, to $139 in 2025.
Across 27 payments — averaging $155.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Biotissue Holdings Inc.$2K
- AbbVie$147
- Merz North America, Inc.$128
- Springworks Therapeutics, Inc.$125
- Galderma Laboratories, L.p.$108
What the payments were for
- Speaking & faculty fees$1,48735%
- Travel & lodging$1,53337%
- Food & beverage$1,15527%
- Education$241%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 14 | $2,084 |
| Biotissue Holdings Inc. | 9 | $1,607 |
| AbbVie | 1 | $147 |
| Merz North America, Inc. | 1 | $128 |
| Springworks Therapeutics, Inc. | 1 | $125 |
| Galderma Laboratories, L.p. | 1 | $108 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,887
- Prokera$1,360
- AmnioGraft$1,360
- AmnioGuard$1,360
- BOTOX$147
- XEOMIN$128
- GOMEKLI$125
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 223 | $2,404 |
| Fluorometholone | 30 | $2,186 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 151 | $1,587 |
| Ofloxacin | 21 | $374 |
| Celecoxib | 22 | $353 |
| Cephalexin | 50 | $215 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 65 | $90 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Ashland
- Roger DaileyPortland$138K
- Francisco CastilloPortland$59K
- Blake FausettEugene$40K
- Davin AshrafPortland$9K
- Tara GoecksBend$2K
- Elizabeth EchalierMedford$2K
- Natalie HoeslyPortland$2K
- Prashanth VallabhanathPortland$1K
- Bryce RadmallOregon City$785
- John NgPortland$400
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.